Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FAAH Inhibitor Trials Could Resume In US Following French Study Disaster Review

Executive Summary

Bial-Portela's drug had 'unique toxicity' not found with other compounds in the class, FDA says; findings could allow studies of Janssen's and Pfizer's investigational FAAH inhibitors that have been on hold to proceed.

You may also be interested in...



Phase I Trials: French Body Urges Transparency, Says Don't Just Follow The Rules

The French committee looking into the devastating failure of the Phase I study with Bial's experimental FAAH inhibitor BIA 10-2474 has called for an international debate on whether data from first-in-human trials of new drugs should be made publicly accessible in order to better protect volunteers taking part in such studies1.

French Trial Tragedy: FDA Launches 'FAAH' Safety Probe

US regulators on Jan. 22 said they are conducting a safety probe of fatty acid amide hydrolase (FAAH) inhibitors being developed and studied in the US after one healthy volunteer in a French Phase I trial testing a product in that class died and five other participants experienced severe adverse neurological events.

French Trial Tragedy: Janssen Halts FAAH Inhibitor Trial

Janssen has voluntarily suspended dosing in two Phase II studies of its experimental FAAH inhibitor JNJ-42165279; the drug is in the same class as the compound at the heart of the clinical trial tragedy in France.

Topics

Related Companies

UsernamePublicRestriction

Register

PS118957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel